Literature DB >> 19318043

New approaches to pharmacotherapy of tumors of the nervous system during childhood and adolescence.

Nina F Schor1.   

Abstract

Tumors of the nervous system are among the most common and most chemoresistant neoplasms of childhood and adolescence. Malignant tumors of the brain collectively account for 21% of all cancers and 24% of all cancer-related deaths in this age group. Neuroblastoma, a peripheral nervous system tumor, is the most common extracranial solid tumor of childhood, and 65% of children with this tumor have only a 10 or 15% chance of living 5 years beyond the time of initial diagnosis. Novel pharmacological approaches to nervous system tumors are urgently needed. This review presents the role of and current challenges to pharmacotherapy of malignant tumors of the nervous system during childhood and adolescence and discusses novel approaches aimed at overcoming these challenges.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19318043      PMCID: PMC2699440          DOI: 10.1016/j.pharmthera.2009.01.001

Source DB:  PubMed          Journal:  Pharmacol Ther        ISSN: 0163-7258            Impact factor:   12.310


  138 in total

1.  Resistance to chemotherapy mediated by TrkB in neuroblastomas.

Authors:  Ruth Ho; Angelika Eggert; Tomoro Hishiki; Jane E Minturn; Naohiko Ikegaki; Patricia Foster; Anna Marie Camoratto; Audrey E Evans; Garrett M Brodeur
Journal:  Cancer Res       Date:  2002-11-15       Impact factor: 12.701

Review 2.  Sphingolipids in neuroblastoma: their role in drug resistance mechanisms.

Authors:  Hannie Sietsma; Anne Jan Dijkhuis; Willem Kamps; Jan Willem Kok
Journal:  Neurochem Res       Date:  2002-08       Impact factor: 3.996

Review 3.  Nonteratomatous tumors in the pediatric sacral region.

Authors:  Cornelius H Lam; Mahmoud G Nagib
Journal:  Spine (Phila Pa 1976)       Date:  2002-06-01       Impact factor: 3.468

4.  Doxorubicin resistant neuroblastoma cells secrete factors that activate AKT and attenuate cytotoxicity in drug-sensitive cells.

Authors:  Mohammad A Emran; Abdelhadi Rebbaa; Bernard L Mirkin
Journal:  Cancer Lett       Date:  2002-08-08       Impact factor: 8.679

5.  Doxorubicin-induced death in neuroblastoma does not involve death receptors in S-type cells and is caspase-independent in N-type cells.

Authors:  Sally Hopkins-Donaldson; Pu Yan; Katia Balmas Bourloud; Annick Muhlethaler; Jean-Luc Bodmer; Nicole Gross
Journal:  Oncogene       Date:  2002-09-05       Impact factor: 9.867

6.  TrkA as a life and death receptor: receptor dose as a mediator of function.

Authors:  Chaohua Yan; Ye Liang; Karen D Nylander; Nina Felice Schor
Journal:  Cancer Res       Date:  2002-09-01       Impact factor: 12.701

7.  Establishment of cisplatin-resistant variants of human neuroblastoma cell lines, TGW and GOTO, and their drug cross-resistance profiles.

Authors:  Iwao Iwasaki; Hisahiko Sugiyama; Shinsaku Kanazawa; Hiromichi Hemmi
Journal:  Cancer Chemother Pharmacol       Date:  2002-04-04       Impact factor: 3.333

8.  Glutathione S-transferase and P-glycoprotein expressions in neuroblastoma.

Authors:  M Tezer Kutlik; Ayşe Ayhan; Safiye Göğüş; Bilgehan Yalçin; Melda Cağlar; Münevver Büyükpamukçu
Journal:  Pediatr Hematol Oncol       Date:  2002 Jul-Aug       Impact factor: 1.969

9.  Ifosfamide/carboplatin/etoposide (ICE) as front-line, topotecan/cyclophosphamide as second-line and oral temozolomide as third-line treatment for advanced neuroblastoma over one year of age.

Authors:  A Donfrancesco; A Jenkner; A Castellano; I Ilari; G M Milano; L De Sio; R Cozza; P Fidani; G Deb; C De Laurentis; A Inserra; C Dominici
Journal:  Acta Paediatr Suppl       Date:  2004-05

10.  Synergistic cytotoxicity of buthionine sulfoximine (BSO) and intensive melphalan (L-PAM) for neuroblastoma cell lines established at relapse after myeloablative therapy.

Authors:  C P Anderson; C P Reynolds
Journal:  Bone Marrow Transplant       Date:  2002-08       Impact factor: 5.483

View more
  7 in total

1.  Wogonin Induced Mitochondrial Dysfunction and Endoplasmic Reticulum Stress in Human Malignant Neuroblastoma Cells Via IRE1α-Dependent Pathway.

Authors:  Wenliang Ge; Qiyou Yin; Hua Xian
Journal:  J Mol Neurosci       Date:  2015-03-05       Impact factor: 3.444

2.  Nuclear condensation and cell cycle arrest induced by telomerase siRNA in neuroblastoma cells.

Authors:  Ming-Dar Tsai; Pei-Rong Chen; Lu-Tai Tien; Yu-Jyun Cai; Yih-Jing Lee
Journal:  J Neurooncol       Date:  2012-12-14       Impact factor: 4.130

Review 3.  The connections between neural crest development and neuroblastoma.

Authors:  Manrong Jiang; Jennifer Stanke; Jill M Lahti
Journal:  Curr Top Dev Biol       Date:  2011       Impact factor: 4.897

4.  HDAC6 regulates neuroblastoma cell migration and may play a role in the invasion process.

Authors:  Linlin Zhang; Ningning Liu; Songbo Xie; Xianfei He; Jun Zhou; Min Liu; Dengwen Li
Journal:  Cancer Biol Ther       Date:  2014       Impact factor: 4.742

5.  A Novel Anticancer Agent, 8-Methoxypyrimido[4',5':4,5]thieno(2,3-b) Quinoline-4(3H)-One Induces Neuro 2a Neuroblastoma Cell Death through p53-Dependent, Caspase-Dependent and -Independent Apoptotic Pathways.

Authors:  Upasana Sahu; Himakshi Sidhar; Pankaj S Ghate; Gopal M Advirao; Sathees C Raghavan; Ranjit K Giri
Journal:  PLoS One       Date:  2013-06-18       Impact factor: 3.240

6.  Thymoquinone-Loaded Soluplus®-Solutol® HS15 Mixed Micelles: Preparation, In Vitro Characterization, and Effect on the SH-SY5Y Cell Migration.

Authors:  Maria Camilla Bergonzi; Marzia Vasarri; Giulia Marroncini; Emanuela Barletta; Donatella Degl'Innocenti
Journal:  Molecules       Date:  2020-10-14       Impact factor: 4.411

Review 7.  Therapeutic effect of natural polyphenols against glioblastoma.

Authors:  Ozal Beylerli; Aferin Beilerli; Alina Shumadalova; Xiaoxiong Wang; Mingchun Yang; Hanran Sun; Lei Teng
Journal:  Front Cell Dev Biol       Date:  2022-10-04
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.